OncoZenge Future Growth
Future criteria checks 5/6
OncoZenge is forecast to grow earnings and revenue by 93.3% and 63.2% per annum respectively while EPS is expected to grow by 105.3% per annum.
Key information
93.3%
Earnings growth rate
105.3%
EPS growth rate
| Pharmaceuticals earnings growth | 21.4% |
| Revenue growth rate | 63.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 22 | 4 | N/A | N/A | 1 |
| 12/31/2025 | 15 | -3 | -10 | -10 | 1 |
| 12/31/2024 | N/A | -9 | -9 | -9 | 1 |
| 9/30/2024 | 0 | -9 | -11 | -11 | N/A |
| 6/30/2024 | 0 | -12 | -13 | -13 | N/A |
| 3/31/2024 | 0 | -14 | -15 | -15 | N/A |
| 12/31/2023 | 0 | -16 | -17 | -17 | N/A |
| 9/30/2023 | N/A | -17 | -17 | -17 | N/A |
| 6/30/2023 | N/A | -16 | -14 | -14 | N/A |
| 3/31/2023 | 0 | -15 | -17 | -17 | N/A |
| 12/31/2022 | N/A | -47 | -22 | -22 | N/A |
| 9/30/2022 | N/A | -43 | -23 | -20 | N/A |
| 6/30/2022 | N/A | -41 | -22 | -19 | N/A |
| 3/31/2022 | N/A | -39 | -20 | -15 | N/A |
| 12/31/2021 | N/A | -4 | -10 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8LY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: 8LY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 8LY is expected to become profitable in the next 3 years.
Revenue vs Market: 8LY's revenue (63.2% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: 8LY's revenue (63.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 8LY's Return on Equity is forecast to be high in 3 years time